PR
Immutep Ltd
PRRUF · OTC
$0.04 -5.25% (-$0.00)
1M -21.86%
Market Cap $82.4M
P/E Ratio -
Div. Yield -
ROE 66.49%
Piotroski F-Score Moderate
4/9Valuation
64 /100
Fair P/B 1.34x
P/S 5.67x
EV/EBITDA N/A
Growth
78 /100
Growing Book val. growth 23.35%
Rev. growth 60.66%
FCF growth N/A
Profitability
20 /100
Weak Net margin 544.79%
Op. margin 576.21%
FCF margin 381.65%
Quality
2 /100
Poor ROE 66.49%
ROA 95.24%
Asset turnover 0.17x
Debt
69 /100
Low Current ratio 5.69x
Int. coverage -1,235.43x
Debt/Equity 0.02x
Stability
23 /100
Unstable Rev. volatility 97.47%
EPS volatility 25.03%
Profitable years 0
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o PRRUF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Marc Voigt
Employees
1,027
Headquarters
Sydney
Prihajajoči dogodki
25 FEB.
Earnings
Upcoming earnings report